QT Imaging Reports 103% Q2 Revenue Growth, Reaffirms Guidance, and Expands Operations
QTI is trading near its 52-week low of $2.51 (15% above the low).
Summary
QT Imaging Holdings announced robust Q2 2026 financial results with significant revenue growth and reaffirmed full-year guidance, alongside key operational and regulatory advancements.
Key Events · Earnings and Guidance · QTI
-
Strong Q2 Revenue Growth
Revenue increased 103% year-over-year to $7.4 million for Q2 2026, with 15 Breast Acoustic CT scanners shipped. First-half revenue grew 116% to $14.0 million.
-
Reaffirmed Full-Year Guidance
The company reiterated its full-year 2026 revenue guidance of approximately $39 million.
-
Debt Maturity Extended
The senior secured term loan maturity was extended by two years to March 2029, though at a higher interest rate (10% to 12%). This resulted in an $8.3 million non-cash loss on debt extinguishment.
-
Operational Milestones Achieved
QT Imaging completed a successful FDA inspection with zero Form 483 observations, expanded manufacturing capacity with a new 22,000 sq ft facility, and secured regulatory authorizations in Israel and Saudi Arabia.
Analysis · QTI · Industrial Applications And Services
QT Imaging Holdings reported strong Q2 2026 revenue growth of 103% year-over-year to $7.4 million, driven by increased scanner shipments. The company reaffirmed its full-year 2026 revenue guidance of $39 million. While net loss increased due to a non-cash debt extinguishment charge, the company achieved significant operational milestones including a successful FDA inspection, expanded manufacturing, and new international regulatory approvals, which are critical for commercial scale-up.
At the time of this filing, QTI was trading at $2.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.4M. The 52-week trading range was $2.51 to $9.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.